First quarter 2026
Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.
Featuring
Olivier Charmeil
Interim Chief Executive Officer
François Roger
Chief Financial Officer
Houman Ashrafian
Head of Research and Development
Highlights
We had a strong start to 2026 with double-digit sales and business EPS growth in the first quarter. We delivered important milestones for patients with five regulatory approvals, all in immunology, one positive phase 3 study readout in rare diseases, and encouraging phase 2 data in respiratory diseases.
Olivier Charmeil
Interim Chief Executive Officer